Key terms
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GNPX news
May 08
6:16pm ET
Genprex CEO Rodney Varner passes away, CFO Ryan Confer succeeds
Apr 03
8:37am ET
Genprex expands clinical trial sites for study of Reqorsa in lung cancer
Apr 03
6:40am ET
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Genprex (GNPX) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
Apr 03
6:31am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evaxion Biotech (EVAX), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Genprex (GNPX)
Mar 25
6:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 25
6:11am ET
Genprex initiated with a Buy at H.C. Wainwright
Mar 19
1:27pm ET
Genprex announces $6.5M registered direct offering priced at the market
Mar 19
8:56am ET
Genprex to sell 1.54M shares at $4.215 in registered direct offering priced ATM
Mar 19
8:39am ET
Genprex to sell 1.54M shares at $4.215 per share
Mar 12
9:02am ET
Genprex receives Notice of Patent Grant for Korean patent
No recent press releases are available for GNPX
GNPX Financials
Key terms
Ad Feedback
GNPX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GNPX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
